CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,838,996 | +46.4% | 1,129,376 | +7.5% | 4.74% | +18.0% |
| Q2 2023 | $11,498,792 | +21.7% | 1,050,118 | -3.0% | 4.02% | +28.8% |
| Q1 2023 | $9,444,789 | +31.7% | 1,083,118 | -5.3% | 3.12% | +10.8% |
| Q4 2022 | $7,169,939 | +58.7% | 1,143,531 | -11.4% | 2.81% | +123.0% |
| Q3 2022 | $4,517,000 | +11.6% | 1,290,511 | -6.0% | 1.26% | -26.1% |
| Q2 2022 | $4,048,000 | +2.3% | 1,372,244 | +7.9% | 1.71% | +169.5% |
| Q1 2022 | $3,957,000 | +4.3% | 1,272,244 | +13.4% | 0.63% | -54.0% |
| Q4 2021 | $3,793,000 | – | 1,122,244 | – | 1.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |